in critical care has a primary goal to promote competency in patient care, medical knowledge, practice-based learning and improvement, and system-based practice to achieve optimal patient outcomes, ultimately to promote excellence in intensive care medicine (13). Scholarly activity measured by publications and grants is important to advance personal academic stature and move our field forward. But the most important focus of critical care fellowship training is teaching critical thinking and compassionate patient care at the bedside. That should be our focus.
I n this issue of Critical Care Medicine, Tsoyi et al (1) have published an exciting work on the beneficial effects of carbon monoxide (CO) that improved efficacy of mesenchymal stromal cells (MSCs). MSCs preconditioned with CO-attenuated organ injury, increased bacterial clearance, promoted resolution of inflammation, and improved survival in mice with polymicrobial sepsis (1) . Importantly, CO preconditioning preserved the efficacy of MSCs when they were administered at 6 hours postsepsis induction time. The salutary effects of these preconditioned cells were mediated by specialized proresolving lipid mediators, particularly D-series resolvins.
Sepsis is a detrimental inflammatory response to infection. Despite its increasing occurrence (10% annually) (2) and high mortality rate (highest in noncardiac ICUs) (3, 4) , there is no Food and Drug Administration-approved drug available that specifically targets this fatal menace. The standard therapy for sepsis is symptomatic, and is becoming less effective due to the antibiotic resistance of microorganisms and potential side effects of vasopressors, such as norepinephrine.
Many successful preclinical basic science studies demonstrating efficacy of various pharmacologic agents in animal models of sepsis have been translated to clinical trials. Unfortunately, none of them advanced to the clinical practice (5) (6) (7) (8) .
Recently, the cellular therapy is becoming an attractive candidate. Particularly, paracrine properties of mesenchymal stem cells (MSCs) have been shown to be important: interleukin-1 receptor antagonist, keratinocyte growth factor, interleukin-10, angiopoietin-1, prostaglandin E2, and antimicrobial factor LL-37 are the most commonly described paracrine soluble factors that have been shown to attenuate severity of acute lung injury (9) . An exciting new trend is the modulation of MSCs to improve their survival, engraftment, and paracrine abilities using different approaches (examples of MSCs modulation to enhance their paracrine activity are summarized in Table 1 ). Although the preconditioning of MSCs with hypoxia is commonly used by investigators (19, 20) , Tsoyi et al (1) first reported beneficial effects of MSCs preconditioned with CO in a murine model of sepsis. Although those inspiring new discoveries are celebrated, there are few issues that scientific community should focus on in the future. Those include the following:
Exploring precise mechanisms of how preconditioned
MSCs work: the question whether the paracrine activity of MSCs, namely the release of various mediators is specific to preconditioning agent should be answered. For instance, the specialized proresolving mediators vary in the nature consisting from different proteins, peptides, gaseous mediators, and specialized lipid mediators, that is, lipoxins, resolvins, protectins, and maresins (21).
Identifying active constituent secreted by MSCs. Although
Tsoyi et al (1) demonstrated that the beneficial effects of CO-preconditioned MSCs were mediated by 5-and 12 of 15-lipoxygenase pathway, specific role of resolvins remains incompletely understood (1) . This is especially the case when the resolvin alone did not affect phagocytic ability of neutrophils (1) . It is quite possible that MSCs paracrine response is none specific to CO or other stimuli. as most of previous successful preclinical studies that have been followed by failed clinical trials used rodent models.
Nevertheless, chemical or mechanical stimulation to enhance potency of MSCs clearly help these cells survive and be metabolically active longer time in harsh in vivo environment associated with severe inflammation. The work by Tsoyi et al (1) shed a new light in this specific field, demonstrating efficacy of CO preconditioning that brought the cell-based therapy to the next level.
